Stock listing

Tradegate:84C0 Clene Inc. Aktie

German listing (Tradegate) of Clene Inc. · home listing NASDAQ:CLNN

Follow Clene Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CLNN

$3.52 USD +0.10 (+2.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CLNN

Past year -59.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.30 – $3.60 USDNov 20, 2026
Volume
143,565 sharesNov 20, 2026
Market cap
$50.69M USDAt the close on Nov 20, 2026 · price × 14.40M shares outstanding
52-week range
$3.02 – $10.84 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$436,932 USDMedian day 107,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Clene Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CLNN · Home$3.52 USD+0.10 (+2.9%)143,565$3.41$3.60$3.30$3.42Close on Nov 20, 2026
Frankfurt:84C0€3.10 EUR+0.06 (+2.0%)—€3.10€3.10€3.10€3.04Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLNN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.52+0.10+2.9%$3.41$3.60$3.30143,565
$3.42+0.20+6.2%$3.23$3.59$3.10239,332
$3.22-0.44-12.0%$3.71$3.71$3.105204,947
$3.66-0.26-6.6%$3.86$3.92$3.54123,344
$3.92-0.08-2.0%$4.43$4.43$3.8628,739
$4.00-0.195-4.6%$4.16$4.25$3.92109,045
$4.195-0.215-4.9%$4.38$4.566$4.17208,437
$4.41+0.03+0.7%$4.40$4.81$4.38145,314
$4.38+0.43+10.9%$3.97$4.93$3.97201,466
$3.95-0.02-0.5%$3.96$4.11$3.75560,703
$3.97-0.13-3.2%$4.04$4.24$3.675116,944
$4.10+0.33+8.8%$3.93$4.24$3.805114,945
$3.77+0.16+4.4%$3.65$3.90$3.6544,308
$3.61-0.22-5.7%$3.85$3.925$3.60554,013
$3.83-0.07-1.8%$3.75$3.95$3.7547,081
$3.90-0.13-3.2%$3.97$3.99$3.8734,114
$4.03+0.06+1.5%$3.96$4.05$3.9043,856
$3.97+0.13+3.4%$3.84$3.99$3.8431,272
$3.84-0.04-1.0%$3.92$3.92$3.7833,858
$3.880.000.0%$3.79$3.97$3.7721,396
$3.88+0.12+3.2%$3.73$4.01$3.63124,247
$3.76+0.03+0.8%$3.76$4.00$3.7184,562
$3.73+0.44+13.4%$3.52$4.05$3.196202,009
$3.29+0.19+6.1%$3.30$3.391$3.1088,490
$3.10-0.21-6.3%$3.39$3.39$3.02204,400
$3.310.000.0%$3.25$3.44$3.20134,000
$3.31-0.08-2.4%$3.38$3.40$3.2471,400
$3.39-0.29-7.9%$3.69$3.70$3.36114,700
$3.68-0.18-4.7%$3.93$3.93$3.6773,700
$3.86-0.02-0.5%$3.83$3.96$3.8048,100
$3.88-0.04-1.0%$3.94$3.96$3.7782,300
$3.92+0.05+1.3%$3.85$4.01$3.7140,500
$3.87-0.04-1.0%$3.92$4.04$3.8045,000
$3.91-0.17-4.2%$4.09$4.11$3.80278,200
$4.08+0.06+1.5%$4.08$4.17$3.9761,500
$4.02-0.06-1.5%$4.10$4.15$4.00100,000
$4.08-0.02-0.5%$4.14$4.33$4.0151,800
$4.10+0.04+1.0%$4.10$4.26$4.0670,400
$4.06-0.24-5.6%$4.24$4.37$4.0191,700
$4.30+0.09+2.1%$4.15$4.49$4.12136,400
$4.21-0.08-1.9%$4.27$4.38$4.0947,700
$4.29-0.09-2.1%$4.36$4.44$4.1575,200
$4.38-0.16-3.5%$4.51$4.70$4.27135,800
$4.54+0.19+4.4%$4.40$4.70$4.40108,900
$4.35+0.20+4.8%$4.16$4.44$4.05191,400
$4.15+0.29+7.5%$3.86$4.23$3.81138,800
$3.86-0.16-4.0%$4.05$4.37$3.84255,800
$4.02+0.74+22.6%$3.25$4.18$3.25478,800
$3.28-0.29-8.1%$3.57$3.72$3.26140,900
$3.57-0.08-2.2%$3.72$3.76$3.52125,000
$3.65-0.07-1.9%$3.67$3.93$3.61113,000
$3.72+0.10+2.8%$3.67$3.84$3.48159,300
$3.62-0.23-6.0%$3.82$3.82$3.60252,600
$3.85-0.15-3.7%$3.92$4.00$3.72122,600
$4.00-0.16-3.8%$4.18$4.22$3.75145,000
$4.16+0.05+1.2%$4.10$4.28$3.88107,600
$4.11-0.17-4.0%$4.22$4.42$4.02159,100
$4.28+0.05+1.2%$4.31$4.32$4.1141,300
$4.23-0.24-5.4%$4.43$4.74$4.1759,700
$4.47-0.18-3.9%$4.67$4.80$4.4033,000
$4.65+0.21+4.7%$4.43$4.75$4.2689,900
$4.44+0.005+0.1%$4.47$4.58$4.20112,100
$4.435+0.115+2.7%$4.31$4.53$4.2437,313
$4.32-0.05-1.1%$4.40$4.41$4.1328,900
$4.37+0.18+4.3%$4.24$4.37$4.1023,100

Splits

1 split · NASDAQ:CLNN · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
Tradegate:84C0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Tradegate
Currency
EUR

What changed lately

Latest news

All Clene Inc. news

Clene Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 126 in all · newest Nov 4, 2026 · oldest 2021
Decks
44 decks · latest Aug 10, 2026

Where Clene Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CLNN · Home listingNASDAQUnited StatesUSD
BOATS:CLNNBOATSUnited StatesUSD
Frankfurt:84C0FrankfurtGermanyEUR
Tradegate:84C0 · This pageTradegateGermanyEUR

Valuation

EV/sales 245× against a median of 5.9×: 5th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$58.31M USD
P/E
Loss
EV/sales
245×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
−80.7%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.48

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Clene Inc. · NASDAQ:CLNNUS$50.69MUS$58.31Mn/a245×n/an/an/an/a1.48
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
iBio, Inc. · NASDAQ:IBIOUS$51.45M−US$23.13Mn/a−21.5×n/a0.7×n/a0.0×2.01
Sirnaomics Ltd. · HKEX:2257US$51.13MUS$69.20Mn/an/an/an/an/an/an/a
Cinclus Pharma Holding AB · OMXSTO:CINPHAUS$51.07MUS$13.13Mn/a3.8×n/a2.6×−765.8%0.0×n/a
Aldeyra Therapeutics, Inc. · NASDAQ:ALDXUS$50.70MUS$9.72Mn/an/an/a1.4×n/a0.0×0.66
Aptamer Sciences, Inc. · KRX:291650US$49.50MUS$34.66Mn/a8.6×n/a1.6×−215.8%0.0×n/a
Acrivon Therapeutics, Inc. · NASDAQ:ACRVUS$49.35M−US$26.60Mn/an/an/a0.7×n/a0.0×2.09
SYNTHAVERSE Spolka Akcyjna · GPW:SVEUS$48.68MUS$70.98Mn/a5.9×n/a1.7×−43.1%0.8×n/a
Median of the othersUS$51.10MUS$23.90M33.0×5.9×1.5×−215.8%0.0×0.66

Forecasts

4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
32.20 USD · Analysts' mean
EPS, year to Dec 2026
-2.62 · 2 analysts
Revenue, year to Dec 2026
188.3K · 4 analysts

Team and board

Officers

OfficerRole
Rob EtheringtonPresident & CEO
Morgan BrownChief Financial Officer
Jerry MiragliaGeneral Counsel and Corporate Secretary
Adam DorfmanVice President, Quality & Technical Operations
Austin RyndersVice President, Clinical Operations
D. Kyle PierceVice President, Research & Development
Benjamin GreenbergHead of Medical
Joanne Zhongyan Zhang M.D.Director of Micro and Biology
Mark MortensonChief Science Officer
Mary Anne McNeilHead of Human Resources
Michael HotchkinChief Development Officer
Rowena GreenExecutive Director, Quality Assurance

Board

DirectorRole
David J. MatlinChairman
Alison H. MoscaBoard Member
Arjun JJ DesaiBoard Member
Jonathon T. GayBoard Member
Matthew KiernanBoard Member
Reed N. WilcoxBoard Member
Rob EtheringtonPresident & CEO
Rowena GreenExecutive Director, Quality Assurance
Shalom JacobovitzBoard Member
Vallerie V. McLaughlinBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+8.8%
Q2 2026Aug 14, 2026 · Before open−1.2%
Q1 2026May 14, 2026 · Before open+8.5%
Q4 2025Mar 12, 2026+2.5%
Q3 2025Nov 13, 2025 · Before open−22.4%
Q2 2025Aug 14, 2025 · Before open−1.4%
Q1 2025May 7, 2025 · Before open−10.5%
Q4 2024Mar 11, 2025 · Before open+3.2%
Q3 2024Nov 13, 2024 · Before open−9.1%
Q2 2024Aug 7, 2024 · Before open−23.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−0.4%
Q4 2023Mar 13, 2024 · Before open−1.0%
Q3 2023Nov 7, 2023 · Before open+8.0%
Q2 2023Aug 14, 2023 · Before open+1.3%
Q1 2023May 12, 2023 · After close+1.7%
Q4 2022Mar 13, 2023 · Before open+7.9%
Q3 2022Nov 7, 2022 · Before open−12.7%
Q2 2022Aug 15, 2022 · Before open+5.8%
Q1 2022May 9, 2022 · Before open−13.5%
Q4 2021Mar 11, 2022 · Before open−3.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck25 slidesAug 10, 2026
Corporate Update (October 2025)Corporate update32 slidesOct 14, 2025
Investor Presentation (November 2024)Investor deck30 slidesNov 13, 2024
Investor Presentation (August 2024)Investor deck38 slidesAug 6, 2024
Technical Presentation (April 2024)Technical10 slidesApr 16, 2024
Technical Presentation (February 2024)Technical13 slidesFeb 22, 2024
Investor Presentation (January 2024)Investor deck34 slidesJan 8, 2024
AAN 2024Conference10 slides2024
Investor Presentation (December 2023)Investor deck32 slidesDec 21, 2023
Corporate Update (November 2023)Corporate update29 slidesNov 7, 2023
All 44 decks
DeckKindSlidesDate
Investor Presentation (September 2023)Investor deck31 slidesSep 25, 2023
Q2 2023 Earnings PresentationEarnings38 slidesAug 14, 2023
Investor Presentation (June 2023)Investor deck37 slidesJun 30, 2023
Investor Presentation (June 2023)Investor deck37 slidesJun 15, 2023
Investor Presentation (April 2023)Investor deck33 slidesApr 17, 2023
Investor Presentation (March 2023)Investor deck29 slidesMar 6, 2023
Investor Presentation (February 2023)Investor deck27 slidesFeb 27, 2023
Technical Presentation (October 2022)Technical19 slidesOct 3, 2022
Investor Presentation (October 2022)Investor deck19 slidesOct 3, 2022
Technical Presentation (August 2022)Technical22 slidesAug 15, 2022
Investor Presentation (August 2022)Investor deck29 slidesAug 15, 2022
Investor Presentation (July 2022)Investor deck21 slidesJul 21, 2022
Investor Presentation (July 2022)Investor deck23 slidesJul 14, 2022
Investor Presentation (May 2022)Investor deck23 slidesMay 9, 2022
Technical Presentation (April 2022)Technical9 slidesApr 5, 2022
Technical Presentation (March 2022)Technical13 slidesMar 14, 2022
Investor Presentation (March 2022)Investor deck35 slidesMar 14, 2022
Investor Presentation (March 2022)Investor deck34 slidesMar 11, 2022
Investor Presentation (December 2021)Investor deck34 slidesDec 17, 2021
Investor Presentation (December 2021)Investor deck19 slidesDec 1, 2021
Investor Presentation (November 2021)Investor deck33 slidesNov 9, 2021
Technical Presentation (November 2021)Technical43 slidesNov 2, 2021
Technical Presentation (October 2021)Technical12 slidesOct 14, 2021
Investor Presentation (October 2021)Investor deck32 slidesOct 7, 2021
Investor Presentation (September 2021)Investor deck32 slidesSep 17, 2021
Investor Presentation (August 2021)Investor deck33 slidesAug 5, 2021
Investor Presentation (May 2021)Investor deck32 slidesMay 12, 2021
Investor Presentation (February 2021)Investor deck31 slidesFeb 26, 2021
Technical Presentation (February 2021)Technical10 slidesFeb 26, 2021
Technical Presentation (February 2021)Technical11 slidesFeb 26, 2021
Technical PresentationTechnical9 slides
Technical PresentationTechnical13 slides
Technical PresentationTechnical34 slides
Technical PresentationTechnical11 slides

Open Decks

Financings

RaiseDate
Registered direct offering of common stock
Closed: US$4M raised · US$3.28 a share
Buyers: David Matlin (Led the offering); Kensington Capital Holdings
Insiders: Led by the Chairman of the Board, David Matlin, alongside the Chief Executive Officer and other existing shareholders including insiders
Use of proceeds: Fund operations through mid-first quarter 2027, beyond the potential FDA decision on accepting the CNM-Au8 NDA for review
Sep 21, 2026
Registered direct offering of common stock
Announced: about US$7M · US$7 a share · Canaccord Genuity LLC
Dealers: Canaccord Genuity LLC (lead)
Use of proceeds: General corporate purposes, NDA filing for CNM-Au8, expanded access and Phase 3 trial, manufacturing expansion, commercialization and early-stage R&D
May 5, 2026
Registered direct offering of common stock with Series A and Series B warrants
Announced: about US$28M · US$6.5 a share · Warrants at US$6 · BTIG, LLC
Dealers: BTIG, LLC (lead)
Buyers: Boxer Capital; Coastlands Capital; Vivo Capital
Insiders: Offering priced above market to new, existing and insider investors, including other current insider investors
Use of proceeds: Fund operations through potential FDA NDA acceptance and approval and commercialization of CNM-Au8 in ALS
Jan 9, 2026
Not stated
Closed: US$1.2M raised
Use of proceeds: Fund operations into the second quarter of 2026
Nov 13, 2025
Equity
Closed: US$1.9M raised
Use of proceeds: To fund operations into the first quarter of 2026
Aug 14, 2025
Convertible debt facility
Made bigger: US$1.5M
Use of proceeds: To fund operations into the first quarter of 2026
Aug 14, 2025
Secured, partially convertible note
Announced: US$10M
Insiders: The note was signed with three entities, all of which are affiliated with Clene
Use of proceeds: Repay the remaining Avenue Capital senior loan and extend cash runway to generate data for the CNM-Au8 ALS drug application
Dec 19, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue200.0K342.0K654.0K473.0K723.0K206.0K0
Cost of revenue43.0K70.0K121.0K26.0K289.0K65.0K900.0K
Gross profit157.0K272.0K533.0K447.0K434.0K141.0K-900.0K
Research and development14.0M20.1M26.7M31.9M28.4M15.2M9.56M6.64M
Selling, general and administrative9.23M13.3M14.4M16.2M18.8M3.26M6.77M2.52M
Operating income-23.1M-33.1M-40.5M-48.4M-50.0M-20.2M-16.3M-323.9K-2.39K
Depreciation and amortization1.50M1.65M1.71M1.02M955.0K963.0K848.0K672.0K
EBITDA-21.6M-31.4M-38.8M-47.4M-49.0M-19.3M-15.5M348.1K
Interest expense2.68M4.06M4.56M3.30M870.0K950.0K88.0K0
Income before tax-26.2M-39.4M-49.5M-29.9M-10.2M-18.9M-16.2M19.4K-2.39K
Income tax0000-428.0K406.0K115.0K-375.3K
Net income-26.2M-39.4M-49.5M-29.9M-9.74M-19.3M-16.2M-277.3K-2.39K
Earnings per share, basic-2.65-5.67-9.43-0.46-0.16-1.10-0.93-0.09-0.00
Earnings per share, diluted-0.16-1.10-0.93

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents5.19M12.2M28.8M18.3M50.3M59.3M8.79M743.8K
Short-term investments06.18M4.98M0
Receivables064.0K143.0K189.0K49.0K21.0K604.0K
Inventory37.0K68.0K37.0K43.0K41.0K191.0K28.0K
Current assets8.98M16.2M38.9M29.2M54.6M63.0M9.48M790.5K
Property, plant and equipment15.2M5.17M4.22M4.32M4.47M
Total assets18.1M27.3M52.3M44.5M63.1M68.2M14.9M47.2M
Accounts payable892.0K1.24M1.50M3.01M1.92M1.12M889.0K1.10M
Current liabilities10.8M10.3M25.3M13.9M6.03M11.7M4.31M222.2K
Long-term debt13.5M15.4M7.15M19.3M14.5M1.95M640.0K
Total debt17.8M20.8M32.2M31.8M24.0M5.92M2.88M3.22M
Total liabilities35.7M36.2M39.0M41.3M50.5M67.9M9.99M42.2M
Shareholders' equity-17.6M-8.86M13.4M3.24M12.6M341.0K-67.8M5.00M
Shares outstanding10.8M8.09M6.42M74.8M62.3M59.5M17.4M3.12M3.12M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-18.5M-21.3M-30.2M-39.0M-34.6M-18.9M-13.2M-205.4K
Capital spending-39.0K-15.0K-330.0K-5.18M-1.33M-387.0K-294.0K-752.0K
Free cash flow-18.6M-21.3M-30.5M-44.2M-36.0M-19.3M-13.5M-957.4K
Cash from investing-39.0K6.32M-1.50M-10.2M-1.33M-387.0K-294.0K-46.0M
Cash from financing11.5M-1.53M42.2M17.2M27.1M69.5M5.50M46.9M
Share buybacks11.8M7.80M31.1M
Change in cash-6.97M-16.7M10.5M-32.0M-8.93M50.5M-7.99M787.8K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
8-K · Current reportOct 19, 2026Material contractSEC
8-K · Current reportOct 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 13, 2026Big-stake noticeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
8-K · Current reportSep 16, 2026Material contractSEC
424B5 · ProspectusSep 16, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2026Big-stake noticeSEC
8-K · Current reportAug 10, 2026Current reportSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 5, 2026Offer documentSEC
SD · Specialized disclosureMay 22, 2026ESG reportSEC
8-K · Current reportMay 22, 2026Material contractSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
8-K · Current reportMay 5, 2026Material contractSEC
424B5 · ProspectusMay 5, 2026Offer documentSEC
424B5 · ProspectusMay 5, 2026Offer documentSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
8-K · Current reportMay 4, 2026Current reportSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 10, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2026Meeting noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
144 · Notice of proposed saleMar 24, 2026Other filingsSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
8-K · Current reportMar 16, 2026Material contractSEC
8-K · Current reportMar 12, 2026ResultsSEC
8-K · Current reportFeb 24, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
8-K · Current reportJan 13, 2026Material contractSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
424B5 · ProspectusJan 9, 2026Offer documentSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
25-NSEDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
8-K · Current reportDec 3, 2025Current reportSEC
8-K · Current reportDec 3, 2025Current reportSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportOct 17, 2025Current reportSEC
424B5 · ProspectusOct 17, 2025Offer documentSEC
8-K · Current reportOct 14, 2025ResultsSEC
4/A · Change in ownership, amendedSep 30, 2025Insider tradeSEC
4/A · Change in ownership, amendedSep 30, 2025Insider tradeSEC
4/A · Change in ownership, amendedSep 30, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
8-K · Current reportSep 25, 2025Current reportSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 15, 2025Other filingsSEC
424B3 · ProspectusSep 12, 2025Offer documentSEC
CORRESP · Letter to the SECSep 10, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 9, 2025Other filingsSEC
8-K · Current reportSep 5, 2025Current reportSEC
424B5 · ProspectusSep 5, 2025Offer documentSEC
S-3 · Registration statementSep 5, 2025Offer documentSEC
S-8 · Registration statement for employee plansSep 5, 2025Offer documentSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportJul 3, 2025Current reportSEC
424B5 · ProspectusJul 3, 2025Offer documentSEC
8-K · Current reportJun 30, 2025Current reportSEC
8-K · Current reportJun 17, 2025Current reportSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Management or board changeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
SD · Specialized disclosureMay 16, 2025ESG reportSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
424B5 · ProspectusApr 28, 2025Offer documentSEC
8-K · Current reportApr 28, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 28, 2025Other filingsSEC
CORRESP · Letter to the SECApr 23, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
8-K · Current reportApr 8, 2025Current reportSEC
PRE 14A · Preliminary proxy statementMar 28, 2025Meeting noticeSEC
UPLOAD · Letter from the SECMar 27, 2025Other filingsSEC
424B5 · ProspectusMar 27, 2025Offer documentSEC
8-K · Current reportMar 27, 2025Current reportSEC
424B5 · ProspectusMar 24, 2025Offer documentSEC
S-3 · Registration statementMar 24, 2025Offer documentSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025ResultsSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
8-K · Current reportMar 12, 2025Current reportSEC

This page holds 200 of 716 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Clene Inc.’s releases · as of Nov 2, 2026

Common shares
14,400,175
Fully diluted
14,400,175

Fully diluted

LineSharesAs of
Common shares14,400,175Nov 2, 2026

Share count over time

CountShares
Nov 2, 202614,400,175

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Scoggin Management LP500K3.5%US$2.04MSep 30, 2026
Boxer Capital Management, LLC478K3.3%US$1.95MSep 30, 2026
Vanguard412K2.9%US$1.68MSep 30, 2026
Ensign Peak Advisors, Inc321K2.2%US$1.31MSep 30, 2026
Empery Asset Management, LP222K1.5%US$904KSep 30, 2026
Cantor Fitzgerald, L. P.140K0.97%US$571KSep 30, 2026
Citadel115K0.80%US$469KSep 30, 2026
Geode Capital113K0.78%US$460KSep 30, 2026
Shay Capital LLC75,8090.53%US$309KSep 30, 2026
BlackRock67,5510.47%US$276KSep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
State Street37,9010.26%US$155KSep 30, 2026
Parsons Capital Management Inc37,2430.26%US$152KSep 30, 2026
Peak6 LLC30,0120.21%US$122KSep 30, 2026
Jane Street25,9390.18%US$106KSep 30, 2026
Lunt Capital Management, Inc.21,2870.15%US$86,851Sep 30, 2026
Morgan Stanley19,7920.14%US$80,751Sep 30, 2026
Northern Trust19,7230.14%US$80,470Sep 30, 2026
ADAR1 Capital Management, LLC15,0000.10%US$61,200Sep 30, 2026
XTX Topco Ltd12,7240.09%US$51,914Sep 30, 2026
Squarepoint Ops LLC11,9200.08%US$48,634Sep 30, 2026
Arax Advisory Partners11,1400.08%US$45,452Sep 30, 2026
Penn Davis McFarland Inc11,0000.08%US$44,880Sep 30, 2026
Two Sigma10,1150.07%US$41,269Sep 30, 2026
Wells Fargo5,9270.04%US$24,182Sep 30, 2026
UBS3,2280.02%US$13,170Sep 30, 2026
PNC Financial Services Group, Inc.2,7350.02%US$11,159Sep 30, 2026
Atlantic Private Wealth, LLC2,2050.02%US$8,996Sep 30, 2026
Steward Partners Investment Advisory, LLC2,0000.01%US$8,160Sep 30, 2026
Nuveen1,8400.01%US$7,544Sep 30, 2026
SBI Securities Co., Ltd.1,025<0.01%US$4,182Sep 30, 2026
Osaic Holdings, Inc.985<0.01%US$4,018Sep 30, 2026
Group One Trading LLC686<0.01%US$2,799Sep 30, 2026
RBC300<0.01%US$1,000Sep 30, 2026
Jones Financial Companies Lllp250<0.01%US$1,075Sep 30, 2026
US Bancorp \de\20<0.01%US$82Sep 30, 2026
BNP Paribas13<0.01%US$53Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund231K1.6%US$1.42MJun 30, 2026
Vanguard Extended Market Index Fund99,5890.69%US$613KJun 30, 2026
Fidelity Extended Market Index Fund46,0260.32%US$302KMay 31, 2026
iShares Micro-Cap ETF26,0270.18%US$160KJun 30, 2026
Fidelity Series Total Market Index Fund12,3970.09%US$81,324May 31, 2026
Fidelity Total Market Index Fund11,3660.08%US$74,561May 31, 2026
Fidelity Nasdaq Composite Index Fund7,4010.05%US$48,551May 31, 2026
Vanguard Balanced Index Fund2,9860.02%US$18,379Jun 30, 2026
1290 VT Micro Cap Portfolio1,7240.01%US$10,611Jun 30, 2026
Total Stock Market Index Trust266<0.01%US$1,637Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Wilcox Reed N
Director
Buy8,000USD 3.42US$27,360Nov 18, 2026
Wilcox Reed N
Director
Buy2,000USD 3.44US$6,880Nov 18, 2026
Ugwumba Chidozie
10% owner
Sale73,296USD 6.20US$454KMay 12, 2026
Ugwumba Chidozie
10% owner
Sale22,177USD 6.75US$150KMay 11, 2026
Ugwumba Chidozie
10% owner
Sale72,884USD 6.80US$496KMay 4, 2026
Ugwumba Chidozie
10% owner
Sale5,795USD 6.01US$34,828May 1, 2026
Ugwumba Chidozie
10% owner
Sale5,736USD 6.08US$34,875Apr 30, 2026
Ugwumba Chidozie
10% owner
Sale12,170USD 5.63US$68,517Apr 29, 2026
Ugwumba Chidozie
10% owner
Sale1,591USD 5.90US$9,387Apr 28, 2026
Ugwumba Chidozie
10% owner
Sale61,345USD 6.14US$377KApr 21, 2026
All 16 trades
TradeTradeSharesPriceValueDate
Ugwumba Chidozie
10% owner
Sale4,318USD 6.12US$26,426Apr 20, 2026
Ugwumba Chidozie
10% owner
Sale25,040USD 6.43US$161KApr 17, 2026
Ugwumba Chidozie
10% owner
Sale7,748USD 6.40US$49,587Apr 16, 2026
Ugwumba Chidozie
10% owner
Sale6,374USD 6.48US$41,304Apr 15, 2026
Ugwumba Chidozie
10% owner
Sale24,925USD 4.81US$120KApr 2, 2026
Ugwumba Chidozie
10% owner
Sale4,278USD 4.97US$21,262Apr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Alison Mosca13.00%1.83MMar 31, 2026Schedule 13G
Vivo Opportunity Fund Holdings, L.P.9.99%1.32MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David J. Matlin
Other companies: TriSalus Life Sciences, Inc. (Director · Since at least Dec 17, 2020); Flagstar Bancorp Inc (Director · Jan 30, 2009 – Jan 20, 2021 · Past); Thornburg Mortgage Inc (Director · Oct 27, 2008 – Dec 29, 2008 · Past); CalAtlantic Group Inc (Director · Jul 29, 2008 – Jun 14, 2017 · Past); Huntsman Corporation (Director · Aug 6, 2007 – Aug 6, 2007 · Past)
Chairman · Since at least Dec 30, 2020
Morgan Brown
Other companies: Lipocine Inc. (Chief Financial Officer · Sep 16, 2013 – Dec 7, 2021 · Past); World Heart Corp (Executive VP · Aug 10, 2009 – Sep 1, 2011 · Past); NPS Pharmaceuticals Inc (Vice President, Finance · Jan 17, 2006 – Oct 17, 2006 · Past)
Chief Financial Officer · Since at least Feb 1, 2022
Arjun JJ Desai
Other companies: Longeveron Inc. (Independent Director · Since at least Jul 2, 2026); TriSalus Life Sciences, Inc. (Director · Since at least Aug 10, 2023)
Board Member · Since at least Sep 18, 2023
Adam DorfmanVice President, Quality & Technical Operations · Since at least Nov 4, 2026
Alison H. MoscaDirector · Since at least Sep 16, 2026
Austin RyndersVice President, Clinical Operations · Since at least Nov 4, 2026
Benjamin GreenbergHead of Medical · Since at least Sep 25, 2025
D. Kyle PierceVice President, Research & Development · Since at least Nov 4, 2026
Fiona CostelloDirector · Dec 30, 2020 – May 18, 2021 · Past
Jerry MiragliaGeneral Counsel and Corporate Secretary · Since at least Nov 4, 2026
All 22 people
PersonSeat
Joanne Zhongyan Zhang M.D.Director of Micro and Biology · Since at least Nov 4, 2026
Jonathon T. GayDirector · Since at least Dec 30, 2020
Mark MortensonChief Science Officer · Since at least Dec 30, 2020
Mary Anne McNeilHead of Human Resources · Since at least Nov 5, 2026
Matthew KiernanBoard Member · Since at least Nov 5, 2026
Michael HotchkinChief Development Officer · Since at least Dec 3, 2025
Reed N. WilcoxBoard Member · Since at least Dec 30, 2020
Robert Dee EtheringtonPresident & CEO, Director · Since at least Sep 16, 2026
Rob EtheringtonPresident & CEO · Since at least Sep 18, 2026
Rowena GreenExecutive Director, Quality Assurance · Since at least Nov 5, 2026
Shalom JacobovitzBoard Member · Since at least Nov 5, 2026
Vallerie V. McLaughlinDirector · Since at least Nov 28, 2023

Open People

Log in to ask 6ix AI your own questions about Clene Inc.